U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H16N4O
Molecular Weight 280.3244
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Y-33075

SMILES

C[C@@H](N)C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2

InChI

InChIKey=JTVBXQAYBIJXRP-SNVBAGLBSA-N
InChI=1S/C16H16N4O/c1-10(17)11-2-4-12(5-3-11)16(21)20-14-7-9-19-15-13(14)6-8-18-15/h2-10H,17H2,1H3,(H2,18,19,20,21)/t10-/m1/s1

HIDE SMILES / InChI

Description

Y-33075 is potent and selective ROCK (Rho-associated coiled-coil-forming protein kinase) inhibitor, developed by Yoshitomi Pharmaceutical Industries for encephalomyelitis treatment. In rabbits and in monkeys, Y-33075 lowers IOP in a dose-dependent fashion. An increase in regenerating axons of RGCs in 100 mM Y-33075-treated eyes is observed compared with saline-treated eyes. Y-33075 dose-dependently increases the number of RGCs with regenerating axons. Both Y-33075 induces a concentration-dependent relaxation in rabbit ciliary arteries precontracted with a high-potassium (high-K) solution. The amplitude of relaxation induced by Y-33075 is not affected by either 100 μM N (G)-nitro-L: -arginine methyl ester (L: -NAME) or 10 μM indomethacin. In Ca2 -free solution, Y-27632 and Y-39983 significantly inhibit the transient contraction of ciliary arteries induced by 10 μM histamine. However, neither Y-27632 nor Y-39983 affects the elevation of [Ca2 ](i) induced by high-K solution and histamine.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
30.0 nM [IC50]
58.0 nM [IC50]
3.6 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Senju Pharmaceuticals completed a phase II trial that evaluated the dose-response relationship of ocular hypotensive efficacy and safety of Y 39983 at concentrations ranging from 0.003%, 0.01%, 0.03% or Y 39983 vehicle control given twice a day for 4 weeks in patients with primary open angle glaucoma or ocular hypertension (UMIN000018866)
Route of Administration: Topical
In Vitro Use Guide
In medium containing 1 uM Y-39983, HUVECs exhibited contraction. The morphologic changes in HUVECs were reversible and had nearly recovered by 1 hour after removal of Y-39983